Genelux (GNLX) Cash from Operations (2022 - 2026)
Genelux (GNLX) posted Cash from Operations of -$6.1 million for Q1 2026, up 1.61% on a QoQ basis from -$6.2 million in Q4 2025, and down 12.24% year-over-year from -$7.0 million in Q1 2025.
Analysis
Genelux (GNLX) Cash from Operations (2022 - 2026) Analysis & Trends
Genelux has reported Cash from Operations for 5 years, with the latest figure at -$6.1 million in Q1 2026.
- On a quarterly basis, Cash from Operations fell 12.24% year-over-year to -$6.1 million in Q1 2026; TTM through Mar 2026 was -$26.0 million, a 16.39% decrease from a year earlier, with the FY2025 full-year figure at -$25.3 million, down 19.18% from the prior year.
- Cash from Operations was -$6.1 million for Q1 2026 at Genelux, up from -$6.2 million in the prior quarter.
- The five-year high for Cash from Operations was $2.8 million in Q1 2022, with the low at -$7.1 million in Q2 2025.
- Average Cash from Operations over 5 years is -$4.8 million, with a median of -$5.4 million recorded in 2025.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations sank 355.2% in 2023, then soared 37.74% in 2024.
- Over 5 years, Cash from Operations stood at -$1.5 million in 2022, then sank by 355.2% to -$6.9 million in 2023, then jumped by 37.74% to -$4.3 million in 2024, then slumped by 44.12% to -$6.2 million in 2025, then advanced by 1.61% to -$6.1 million in 2026.
- The last three Cash from Operations figures came in at -$6.1 million (Q1 2026), -$6.2 million (Q4 2025), and -$6.6 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 4.00 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 3.57 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.13 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 813.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -526.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 448.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -270.50 Mn |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - | -6.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -6.10 Mn |
| Dec 31, 2025 | -6.20 Mn |
| Sep 30, 2025 | -6.60 Mn |
| Jun 30, 2025 | -7.07 Mn |
| Mar 31, 2025 | -5.44 Mn |
| Dec 31, 2024 | -4.30 Mn |
| Sep 30, 2024 | -5.75 Mn |
| Jun 30, 2024 | -6.82 Mn |
| Mar 31, 2024 | -4.35 Mn |
| Dec 31, 2023 | -6.91 Mn |
| Sep 30, 2023 | -3.36 Mn |
| Jun 30, 2023 | -5.42 Mn |
| Mar 31, 2023 | -4.59 Mn |
| Dec 31, 2022 | -1.52 Mn |
| Mar 31, 2022 | 2.83 Mn |